Form 4: Clene Inc. Director Receives Stock Option Grant

Director Reed N. Wilcox was granted stock options for 3,564 shares of Clene Inc. common stock on May 21, 2026.

Summary

• Director Reed N. Wilcox received two separate stock option grants totaling 3,564 shares of Clene Inc. (CLNN) common stock.
• The options carry an exercise price of $6.81 per share.
• 1,500 shares vest in 12 equal monthly installments starting June 21, 2026.
• 2,064 shares vested immediately upon the grant date of May 21, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation with no material impact on the company's financial trajectory.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Dilutive impact of new stock option grants on existing shareholders.

Risks

• Potential for future dilution if options are exercised.
• Market price volatility affecting the value of the granted options.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term performance and align leadership with shareholder outcomes in the biotechnology sector.

Comparison to Industry Standards

• The use of the 2020 Stock Plan for director compensation is consistent with standard practices for small-cap biotechnology firms.
• Immediate vesting of a portion of the grant is a common mechanism for director compensation in the industry.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new stock options.

Next Steps

• Vesting of the 1,500 share grant in monthly installments beginning June 21, 2026.

Key Dates

Keywords

Clene Inc, CLNN, Form 4, Insider Trading, Stock Options, Director Compensation